SCHEMBL9898472

SCHEMBL9898472

CN(C)CCOC(CCSSCCC(OCCN(C)C)[SiH](C)C)[SiH](C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.33
CYP1A2 P05177 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
CHRM1 P11229 1/20 0.33
TSHR P16473 1/20 0.33
ADRA2B P18089 1/20 0.33
CHRM3 P20309 1/20 0.33
SLC6A2 P23975 1/20 0.33
HRH2 P25021 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
OPRM1 P35372 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9896912 0.93 LMNA (0.32) LMNACYP1A2CHRM2CHRM4CHRM5
SCHEMBL9898586 0.82 MEN1 (0.31)
SCHEMBL9897397 0.76
SCHEMBL27863697 0.75 CHRM2 (0.36) LMNACYP1A2CHRM2CHRM4CHRM5
SCHEMBL671566 0.74 THRB (0.32) LMNA
SCHEMBL3693727 0.69
SCHEMBL15240221 0.67
SCHEMBL444238 0.67
SCHEMBL3854114 0.63
SCHEMBL10794918 0.62 CHRM2 (0.46) LMNACYP1A2CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150595-B2 Process for producing silane coupling agent BRIDGESTONE CORPORATION (JP) 2015-10-06 US claimed
EP-2471798-B1 PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS BRIDGESTONE CORP (JP) 2015-08-19 EP claimed
EP-2471798-A1 PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS Bridgestone Corporation (JP) 2012-07-04 EP claimed
US-20120149929-A1 PROCESS FOR PRODUCING SILANE COUPLING AGENT BRIDGESTONE CORPORATION (JP) 2012-06-14 US claimed
US-9150595-B2 Process for producing silane coupling agent BRIDGESTONE CORPORATION (JP) 2015-10-06 US disclosed
EP-2471798-B1 PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS BRIDGESTONE CORP (JP) 2015-08-19 EP disclosed
EP-2471798-A1 PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS Bridgestone Corporation (JP) 2012-07-04 EP disclosed
US-20120149929-A1 PROCESS FOR PRODUCING SILANE COUPLING AGENT BRIDGESTONE CORPORATION (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149929-A1 PROCESS FOR PRODUCING SILANE COUPLING AGENT HAO2, SAMM50, SKP2 LMNA 3112/4885CYP1A2 689/4885CHRM2 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.